Dark

Check out our Dark Pool Levels

BLRX
BioLineRX Ltd
stock NASDAQ ADR

At Close

Jul 31, 2026 3:57:28 PM EDT

2.76USD+2.222%(+0.06)9,651

0.00Bid 0.00Ask 0.00Spread

Pre-market

0.00USD-100.000%(-2.70)0

After-hours

0.00USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 24, 2022

07:06AM EST BioLine Rx Completes Enrollment for its 1/2a Study of an Intratumoral Cancer Vaccine Benzinga

07:01AM EST BioLineRx Announces Completion of Enrollment of Phase 1/2a Study of Innovative PR Newswire

Jan 18, 2022

07:06AM EST BioLineRx Completes Pre-NDA Meeting With FDA For Motixafortide For Stem Cell Mobilization In Multiple Myeloma Patients RTTNews

07:05AM EST BioLineRx Announces Completion Of Pre-NDA Meeting With FDA For Motixafortide For Stem Cell Mobilization In Multiple Myeloma Patients Benzinga

07:01AM EST BioLineRx Announces Successful Completion of Pre-NDA Meeting with FDA for PR Newswire

Dec 17, 2021

08:56AM EST BioLineRx Plans Pre-NDA Meeting For Motixafortide Plus RTTNews

07:10AM EST BioLineRx Reports Successful Phase 3 Trial Of Motixafortide Plus G-CSF For Stem Cell Mobilization In Multiple Myeloma RTTNews

07:01AM EST BioLineRx Provides Highlights from Oral Presentation Delivered at the 63rd PR Newswire

Dec 15, 2021

07:15AM EST BioLineRx Announces Formation Of Immuno-Oncology Scientific Advisory Board Benzinga

07:01AM EST BioLineRx Announces Formation of Immuno-Oncology Scientific Advisory Board (SAB) PR Newswire

Dec 10, 2021

02:34PM EST Mid-Day Market Update: Oracle Gains Following Upbeat Q2 Results; Angion Biomedica Shares Drop Benzinga

Nov 18, 2021

07:30AM EST BioLine Rx Q3 EPS $(0.01) Beats $(0.16) Estimate Benzinga

07:14AM EST BioLineRx Q3 Net Loss Widens To $5.7 Mln, From $4.6 Mln Prior Year RTTNews

07:02AM EST BioLineRx Reports Third Quarter 2021 Financial Results and Provides Corporate PR Newswire

05:01AM EST Earnings Scheduled For November 18, 2021 Benzinga

Nov 12, 2021

07:17AM EST BioLineRx to Report Third Quarter 2021 Results on November 18, 2021 PR Newswire

Nov 4, 2021

09:18AM EDT BioLineRx Announces An Oral Presentation And Three Poster Presentations RTTNews

09:16AM EDT BioLineRx Announces an Oral Presentation and Three Poster Presentations at the PR Newswire

Oct 13, 2021

01:38PM EDT BioLineRx Announces Results From Pharmacoeconomic Study Evaluating Cost-Effectiveness Of Motixafortide As A Primary Stem Cell Mobilization Agent Benzinga

09:05AM EDT BioLineRx Ltd. (BLRX) reported positive results from a pharmacoeconomic study evaluating the cost-effectiveness of using investigational drug Motixafortide as a primary stem cell mobilization agent on top of granulocyte colony stimulating factor, versus G-CSF alone, in multiple myeloma patients undergoing autologous stem cell transplantation. RTTNews

08:33AM EDT BioLineRx Reports Positive Results From Study Positioning Motixafortide As Standard Of Care In Stem Cell Mobilization RTTNews

08:31AM EDT BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning PR Newswire

Aug 18, 2021

07:19AM EDT BioLineRx Reports Q2 Net Loss Of $6.8 Mln Same With Last Year RTTNews

07:07AM EDT BioLine Rx Q2 EPS $(0.01) Beats $(0.15) Estimate Benzinga

07:01AM EDT BioLineRx Reports Second Quarter 2021 Financial Results and Provides Corporate PR Newswire

05:35AM EDT Earnings Scheduled For August 18, 2021 Benzinga

Aug 12, 2021

09:31AM EDT BioLineRx to Report Second Quarter 2021 Results on August 18, 2021 PR Newswire

May 26, 2021

07:33AM EDT The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing Benzinga

07:18AM EDT BioLine Rx Q1 EPS $(0.02) Beats $(0.15) Estimate Benzinga

07:16AM EDT BioLineRx Q1 Loss Per Share $0.02 Vs Loss $0.04 Last Year RTTNews

07:01AM EDT BioLineRx Reports First Quarter 2021 Financial Results and Provides Corporate PR Newswire

04:12AM EDT Earnings Scheduled For May 26, 2021 Benzinga

May 20, 2021

07:01AM EDT BioLineRx to Report First Quarter 2021 Results on May 26, 2021 PR Newswire

May 5, 2021

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

May 4, 2021

03:00PM EDT Mid-Afternoon Market Update: Nasdaq Tumbles 300 Points; Neuronetics Shares Spike Higher Benzinga

01:46PM EDT Hearing Oppenheimer Reiterates Outperform Rating And $10 Price Target On BioLineRx Benzinga

01:36PM EDT Maxim Raises BioLineRx Price Target From $5 To $10 Benzinga

01:27PM EDT Hearing Maxim Raised BioLineRx Price Target To $10; Unconfirmed Benzinga

12:20PM EDT Mid-Day Market Update: Maxar Technologies Falls After Q1 Results; BioLineRx Shares Climb Benzinga

10:55AM EDT BioLineRx Shares Quiet Following US Patent & Trademark Office Abstract For Co.'s 'Methods of treating acute myeloid leukemia' Benzinga

10:25AM EDT Mid-Morning Market Update: Markets Open Lower; Pfizer Raises FY21 Outlook Benzinga

10:08AM EDT BioLineRx Ltd. (BLRX) shares are gaining more than 83 percent on Tuesday morning trade, on more than average volume, after the company said its Genesis phase 3 trial of Motixafortide in multiple myeloma patients met all primary and secondary endpoints. RTTNews

08:19AM EDT BioLineRx Stock Is Trading Higher As Motixafortide-G-CSF Combo Shows Promise In Transplant Setting For Multiple Myeloma Patients Benzinga

08:10AM EDT The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data Benzinga

07:21AM EDT BioLineRx Announces Positive Top-Line Results From GENESIS Phase 3 Trial Of Motixafortide RTTNews

07:07AM EDT UPDATE: BioLine Rx Says 'An analysis of data on all 122 enrolled patients...found highly statistically significant evidence across all primary and secondary endpoints favoring Motixafortide in addition to G-CSF;' Shares Set To Resume Trade At 7:30 a.m. ET Benzinga

07:05AM EDT BioLineRx Announces Top-Line Results from GENESIS Phase 3 Trial Of Motixafortide In Stem-Cell Mobilization For Autologous Bone Marrow Transplantation in Multiple Myeloma Patients; Shares Previously Halted On Code News Pending Benzinga

07:01AM EDT Motixafortide in Stem-Cell Mobilization for Autologous Bone Marrow Transplantation in Multiple Myeloma Patients PR Newswire

Apr 15, 2021

07:26AM EDT BioLineRx Says On Track To Report Final Data From Phase 3 GENESIS Trial Of Motixafortide RTTNews

07:16AM EDT BioLineRx To Present At 2021 American Association For Cancer Research Annual Meeting Benzinga

07:15AM EDT BioLineRx Announces Presentation at 2021 American Association for Cancer PR Newswire

Feb 23, 2021

11:25AM EST HC Wainwright & Co. Maintains Buy on BioLine Rx, Lowers Price Target to $19 Benzinga

07:18AM EST BioLineRx FY Net Loss $30.02 Mln Vs. Net Loss $25.5 Mln Last Year RTTNews

07:05AM EST BioLineRx FY20 EPS $(0.21), Says Had Cash And Equivalents Of $22.6M As Of Dec. 31 Benzinga

07:01AM EST BioLineRx Reports Year-End 2020 Financial Results and Provides Corporate Update PR Newswire

04:09AM EST Earnings Scheduled For February 23, 2021 Benzinga

Feb 17, 2021

07:10AM EST BioLineRx to Report Annual 2020 Results on February 23, 2021 PR Newswire

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Jan 22, 2021

04:15PM EST BioLineRx Announces Closing of $34.5 Million Bought Deal Offering and Full PR Newswire

Jan 20, 2021

10:19AM EST Mid-Morning Market Update: Markets Open Higher; Morgan Stanley Beats Q4 Expectations Benzinga

07:32AM EST The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga

Jan 19, 2021

09:43PM EST BioLineRx Increases Previously Announced Bought Deal Offering to $30 Million PR Newswire

04:56PM EST BioLineRx Announces $10 Million Bought Deal Offering PR Newswire

Dec 16, 2020

02:30PM EST Mid-Afternoon Market Update: Dow Drops 100 Points; Fed Keeps Interest Rates Unchanged Benzinga

01:43PM EST HC Wainwright & Co. Maintains Buy on BioLine Rx, Raises Price Target to $22 Benzinga

01:00PM EST Mid-Morning Market Update: Markets Mostly Flat; Aphria and Tilray To Merge Benzinga

12:59PM EST Mid-Day Market Update: Dow Falls 50 Points; Sio Gene Therapies Shares Surge Benzinga

10:28AM EST Mid-Morning Market Update: Markets Mostly Flat; Aphria and Tilray To Merge Benzinga

10:27AM EST Mid-Morning Market Update: Markets Edge Lower; Aphria and Tilray To Merge Benzinga

07:15AM EST The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal Benzinga

06:13AM EST BioLineRx Reports Results From Phase 2a Combination Study RTTNews

06:07AM EST BioLineRx Announces Final Results From Phase 2a COMBAT/KEYNOTE-202 Triple Combination Study Of Motixafortide In Second Line Metastatic Pancreatic Cancer; Results 'showed substantial improvement as compared to historical results across all study endpoints' Benzinga

06:04AM EST BioLineRx Announces Results From Triple Combination Arm Of COMBAT/KEYNOTE-202 Clinical Study RTTNews

06:02AM EST Combination Study of Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC) PR Newswire

Dec 15, 2020

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Nov 23, 2020

07:15AM EST BioLineRx Q3 Net Loss $4.6 Mln Vs Loss $3.9 Mln Last Year RTTNews

07:15AM EST BioLine Rx Q3 EPS $(0.02) Beats $(0.35) Estimate Benzinga

07:01AM EST BioLineRx Reports Third Quarter 2020 Financial Results and Provides Corporate PR Newswire

04:05AM EST Earnings Scheduled For November 23, 2020 Benzinga

Nov 18, 2020

07:18AM EST BioLineRx Initiates Phase 1b Trial In Patients With ARDS Secondary To COVID-19 And Other Respiratory Viral Infections RTTNews

07:02AM EST BioLineRx Announces Initiation Of Phase 1b Clinical Trial In Patients With Acute Respiratory Distress Syndrome Secondary To COVID-19 And Other Respiratory Viral Infections Benzinga

07:02AM EST Acute Respiratory Distress Syndrome (ARDS) Secondary to COVID-19 and Other Respiratory Viral Infections PR Newswire

07:01AM EST BioLineRx to Report Third Quarter 2020 Results on November 23, 2020 PR Newswire

Nov 4, 2020

08:21AM EST The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings Benzinga

Nov 3, 2020

10:29AM EST Yahoo Finance Trending Stocks For Tuesday, Nov. 3, 2020: FSR, BLRX, TDOC, MPW, SRNE, TSLA, PYPL, SQ, SBE, O Benzinga

Nov 2, 2020

10:44AM EST Yahoo Finance Trending Stocks For Monday, Nov. 2, 2020: FSR, BLRX, TDOC, MPW, SRNE, TSLA, PYPL, SQ, SBE, O Benzinga

Oct 30, 2020

07:23AM EDT BioLineRx Announces Positive Results From Interim Analysis Of GENESIS Phase 3 Trial Of Motixafortide RTTNews

07:08AM EDT BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization Benzinga

07:01AM EDT BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 PR Newswire

Oct 29, 2020

08:54AM EDT BioLinRx Reports Initiation Of Phase 2 Trial In First-Line Metastatic Pancreatic Cancer Benzinga

08:53AM EDT BioLineRx Begins Phase 2 Clinical Trial In First-Line Metastatic Pancreatic Cancer RTTNews

08:49AM EDT BioLineRx Announces Initiation of Phase 2 Clinical Trial in First-Line PR Newswire

Aug 19, 2020

12:42PM EDT BioLine shares are trading higher after the company announced it has achieved its enrollment target in the phase 3 GENESIS trial for planned interim analysis. Benzinga

07:03AM EDT BioLineRx Achieves Enrollment Target In Phase 3 GENESIS Trial For Planned Interim Analysis RTTNews

07:01AM EDT BioLineRx Achieves Enrollment Target in Phase 3 GENESIS Trial for Planned PR Newswire

07:01AM EDT BioLineRx Achieves Enrollment Target In Phase 3 GENESIS Trial For Planned Interim Analysis Benzinga

Aug 6, 2020

09:10AM EDT BioLine Rx Q2 EPS $(0.03) Beats $(0.73) Estimate Benzinga

08:53AM EDT BioLineRx Q2 Operating Loss $5.6M vs Loss $6.5M In Same Qtr. Last Year Benzinga

07:28AM EDT BioLineRx Q2 Net Loss $6.8 Mln Vs Net Loss $5.5 Mln Last Year RTTNews

07:19AM EDT BioLine Rx Ltd Held $27.3M In Cash, Cash Equivalents And Short-Term Bank Deposits As Of June 30, 2020 Benzinga

07:01AM EDT BioLineRx Reports Second Quarter 2020 Financial Results and Provides Corporate PR Newswire

Aug 5, 2020

01:22PM EDT BioLineRx Granted Australian Patent Number 2014343214 Titled 'Methods of treating acute myeloid leukemia with a FLT3 mutation' Benzinga

Jul 31, 2020

07:36AM EDT BioLine Rx Q1 GAAP EPS $(0.04) Beats $(0.66) Estimate Benzinga

07:00AM EDT BioLineRx to Report Second Quarter 2020 Results on August 6, 2020 PR Newswire

Share